TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis (TB)
(WorldNews Netherlands)

Regimens under clinical development include treatment options for drug-resistant forms of TB NEW YORKand HERTFORDSHIRE, Englandand PITTSBURGH, April 18, 2019/PRNewswire / -- Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan N.V. (NASDAQ: MYL), today announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB). TB, a bacterial infection transmitted through the air, is a challenging disease to treat, often requiring treatment through a combination of antibiotics. It also is the leading cause of death among people with HIV/AIDS2 and accounts for more than 1 in 4...